Produção Nacional
Revisado por pares
Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective study
2023; Springer Science+Business Media; Volume: 72; Issue: 11 Linguagem: Inglês
10.1007/s00262-023-03518-z
ISSN1432-0851
AutoresOndřej Fiala, Sebastiano Buti, Hideki Takeshita, Y. Okada, Francesco Massari, Geòrgia Anguera, Michele Dionese, Sarah Scagliarini, Thomas Büttner, Giuseppe Fornarini, Zin Myint, Luca Galli, Vinícius Carrera Souza, Renate Pichler, Ugo De Giorgi, María Natalia Gandur Quiroga, Danielle Gilbert, Lazar Popović, Enrique Grande, Giulia Mammone, Rossana Berardi, Simon J. Crabb, Javier Molina‐Cerrillo, Marcelo Freitas, Murilo Luz, Roberto Iacovelli, Fabio Calabrò, Deniz Tural, Francesco Atzori, Zsófia Kürönya, Rita Chiari, Saul Campos‐Gómez, Orazio Caffo, André P. Fay, Jakub Kucharz, Paolo Andrea Zucali, José Augusto Rinck, Annalisa Zeppellini, Diogo Assed Bastos, Gaetano Aurilio, Augusto Mota, Karine Martins da Trindade, Cinzia Ortega, Juan Pablo Sade, Mimma Rizzo, Nuno Vau, Patrizia Giannatempo, Allan Barillas, Fernando Sabino Marques Monteiro, Breno Dauster, Carlo Cattrini, Lucas Nogueira, Roni de Carvalho Fernandes, Emmanuel Seront, Luis García Aceituno, Francesco Grillone, Hernan Javier Cutuli, Mauricio Fernández, Maria Bassanelli, Giandomenico Roviello, Halima Abahssain, Giuseppe Procopio, Michèle Milella, Jindřich Kopecký, Angelo Martignetti, Carlo Messina, Manuel Caitano, Eva Inman, Ravindran Kanesvaran, Daniel Herchenhorn, Daniele Santini, Ray Manneh Kopp, Renato Bisonni, Roubini Zakopoulou, Alessandra Mosca, Francesco Morelli, Fernando Cotait Maluf, Andrey Soares, Fernando Furlan Nunes, Álvaro Pinto, Anca Zgură, Lorena Incorvaia, Jawaher Ansari, Ignacio Ortego Zabalza, Johannes Landmesser, Alessandro Rizzo, Veronica Mollica, Giulia Sorgentoni, Nicola Battelli, Camillo Porta, Joaquim Bellmunt, Matteo Santoni,
Tópico(s)Urinary and Genital Oncology Studies
ResumoConcomitant medications may potentially affect the outcome of cancer patients. In this sub-analysis of the ARON-2 real-world study (NCT05290038), we aimed to assess the impact of concomitant use of proton pump inhibitors (PPI), statins, or metformin on outcome of patients with metastatic urothelial cancer (mUC) receiving second-line pembrolizumab. We collected data from the hospital medical records of patients with mUC treated with pembrolizumab as second-line therapy at 87 institutions from 22 countries. Patients were assessed for overall survival (OS), progression-free survival (PFS), and overall response rate. We carried out a survival analysis by a Cox regression model. A total of 802 patients were eligible for this retrospective study; the median follow-up time was 15.3 months. PPI users compared to non-users showed inferior PFS (4.5 vs. 7.2 months, p = 0.002) and OS (8.7 vs. 14.1 months, p < 0.001). Concomitant PPI use remained a significant predictor of PFS and OS after multivariate Cox analysis. The use of statins or metformin was not associated with response or survival. Our study results suggest a significant prognostic impact of concomitant PPI use in mUC patients receiving pembrolizumab in the real-world context. The mechanism of this interaction warrants further elucidation.
Referência(s)